Joshua S Adler, MD
Internal Medicine · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 36 years
- University of California, San Diego School of Medicine, 1990
Offices
2 locations · University of California San Francisco · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Adler’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G73842 · Current
Licensed to practise in California · since 1992 · expires 2028-02-29 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$6,777
Medicare paid this office $6,777 for 38 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $2,027 | $156 |
| Return visit (30+ min) | 17 | $1,866 | $69 |
| Short return visit (20+ min) | 15 | $1,530 | $53 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 11 | $193 | $15 |
Who their Medicare patients are
38 Original Medicare patients in 2024. Average age 79 · Women 40% · Also on Medicaid 0% · Health risk score 1.19. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 74% · Chronic kidney disease 32%.
The office billed $42,804, Medicare allowed $8,975 and paid $6,777; for 97 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 38 | 97 | 79 | 1.19 | $42,804 | $6,777 |
| 2023 | 34 | 68 | 78 | 1.13 | $33,175 | $4,806 |
| 2022 | 38 | 71 | 77 | 1.20 | $36,017 | $5,592 |
| 2021 | 43 | 65 | 73 | 1.11 | $33,066 | $5,148 |
| 2020 | 31 | 41 | 77 | 1.17 | $19,275 | $1,961 |
| 2019 | 38 | 56 | 77 | 1.04 | $28,040 | $2,904 |
| 2018 | 38 | 69 | 79 | 0.94 | $33,669 | $3,689 |
| 2017 | 48 | 84 | 77 | 0.98 | $37,913 | $4,029 |
| 2016 | 50 | 142 | 76 | 1.49 | $66,186 | $9,951 |
| 2015 | 76 | 202 | 75 | 1.71 | $95,512 | $15,416 |
| 2014 | 71 | 157 | 75 | 1.83 | $67,859 | $10,786 |
| 2013 | 62 | 138 | 75 | 1.47 | $52,985 | $8,014 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 17 | $1,609 | $73 |
| Short return visit (20+ min) | 13 | $954 | $43 |
2022: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,995 | $153 |
| Short return visit (20+ min) | 18 | $1,620 | $51 |
| Return visit (30+ min) | 12 | $992 | $66 |
2021: 2 services
| Return visit (30+ min) | 22 | $1,802 | $69 |
| Short return visit (20+ min) | 14 | $836 | $52 |
2020: 2 services
| Return visit (30+ min) | 19 | $1,138 | $52 |
| Short return visit (20+ min) | 12 | $649 | $46 |
2019: 2 services
| Return visit (30+ min) | 23 | $1,755 | $65 |
| Short return visit (20+ min) | 19 | $726 | $33 |
2018: 2 services
| Return visit (30+ min) | 26 | $2,225 | $57 |
| Short return visit (20+ min) | 13 | $775 | $39 |
2017: 2 services
| Return visit (30+ min) | 29 | $2,347 | $56 |
| Short return visit (20+ min) | 21 | $1,002 | $36 |
2016: 2 services
| Return visit (30+ min) | 32 | $3,060 | $62 |
| Short return visit (20+ min) | 12 | $764 | $38 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $6,085 | $94 |
| Return visit (30+ min) | 39 | $2,937 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,001 | $182 |
| Short return visit (20+ min) | 18 | $1,328 | $43 |
| Hospital discharge day management, 30 minutes or less | 11 | $736 | $67 |
2014: 3 services
| Return visit (30+ min) | 32 | $2,648 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,801 | $64 |
| Short return visit (20+ min) | 29 | $1,600 | $43 |
2013: 2 services
| Return visit (30+ min) | 32 | $2,452 | $56 |
| Short return visit (20+ min) | 26 | $1,799 | $40 |
Drugs they prescribed that Part D paid
$47,195
Pharmacies billed $47,195 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (11 of 623) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
567 generic and fewer than 11 brand-name prescriptions · $47,195 in drug cost · 12 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Olanzapine | 14 | $2,847 | $203 |
| Ezetimibe | 19 | $2,467 | $130 |
| Atorvastatin | 37 | $892 | $24 |
| Escitalopram | 18 | $700 | $39 |
| Olanzapine Odt | 12 | $692 | $58 |
See all 16 drugs
| Olanzapine | 14 | $2,847 | $203 |
| Ezetimibe | 19 | $2,467 | $130 |
| Atorvastatin | 37 | $892 | $24 |
| Escitalopram | 18 | $700 | $39 |
| Olanzapine Odt | 12 | $692 | $58 |
| Losartan | 27 | $521 | $19 |
| Benazepril | 24 | $407 | $17 |
| Simvastatin | 17 | $389 | $23 |
| Amlodipine Besylate | 21 | $358 | $17 |
| Metoprolol | 27 | $345 | $13 |
| Tamsulosin | 14 | $303 | $22 |
| Allopurinol | 19 | $274 | $14 |
| Omeprazole | 15 | $255 | $17 |
| Hydrochlorothiazide | 45 | $150 | $3 |
| Lisinopril | 12 | $138 | $12 |
| Metoprolol | 11 | $33 | $3 |
Year by year
| 2024 | 623 | 51 | 2% (11) | None | $47,195 |
| 2023 | 610 | 45 | None | None | $42,364 |
| 2022 | 511 | 56 | 3% (15) | None | $36,015 |
| 2021 | 510 | 74 | 5% (27) | 9% | $33,515 |
| 2020 | 467 | 64 | 4% (20) | 8% | $25,337 |
| 2019 | 528 | 68 | 3% (18) | 13% | $32,293 |
| 2018 | 508 | 97 | 11% (54) | 10% | $34,572 |
| 2017 | 678 | 149 | 15% (100) | None | $45,446 |
| 2016 | 763 | 116 | 8% (57) | None | $49,419 |
| 2015 | 758 | 169 | 16% (119) | 16% | $39,999 |
| 2014 | 756 | 153 | 15% (111) | 17% | $35,439 |
| 2013 | 758 | 155 | 15% (115) | None | $36,098 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Synthroid | 13 | $1,168 | $90 |
| Atorvastatin | 39 | $997 | $26 |
| Tamsulosin | 18 | $898 | $50 |
| Losartan | 29 | $805 | $28 |
| Amlodipine Besylate | 35 | $537 | $15 |
| Memantine | 14 | $448 | $32 |
| Ezetimibe | 18 | $397 | $22 |
| Metoprolol | 24 | $372 | $16 |
| Hydrochlorothiazide | 54 | $310 | $6 |
| Omeprazole | 16 | $244 | $15 |
| Benazepril | 21 | $221 | $11 |
| Allopurinol | 13 | $188 | $14 |
| Simvastatin | 17 | $166 | $10 |
| Trazodone | 15 | $115 | $8 |
| Escitalopram | 15 | $68 | $5 |
2022: 15 drugs
| Tamsulosin | 19 | $874 | $46 |
| Synthroid | 13 | $831 | $64 |
| Losartan | 21 | $692 | $33 |
| Terazosin | 20 | $623 | $31 |
| Atorvastatin | 21 | $592 | $28 |
| Amlodipine Besylate | 37 | $448 | $12 |
| Benazepril | 21 | $354 | $17 |
| Ezetimibe | 11 | $329 | $30 |
| Simvastatin | 18 | $267 | $15 |
| Metoprolol | 14 | $217 | $15 |
| Omeprazole | 12 | $212 | $18 |
| Hydrochlorothiazide | 39 | $153 | $4 |
| Allopurinol | 11 | $149 | $14 |
| Paroxetine | 12 | $81 | $7 |
| Gabapentin | 13 | $74 | $6 |
2021: 13 drugs
| Ezetimibe | 12 | $622 | $52 |
| Tamsulosin | 23 | $603 | $26 |
| Atorvastatin | 17 | $383 | $23 |
| Benazepril | 33 | $379 | $11 |
| Terazosin | 12 | $327 | $27 |
| Amlodipine Besylate | 42 | $300 | $7 |
| Losartan | 16 | $281 | $18 |
| Duloxetine | 11 | $196 | $18 |
| Hydrochlorothiazide | 44 | $157 | $4 |
| Allopurinol | 11 | $135 | $12 |
| Simvastatin | 16 | $120 | $7 |
| Oxycodone | 18 | $114 | $6 |
| Paroxetine | 12 | $27 | $2 |
2020: 14 drugs
| Synthroid | 16 | $1,545 | $97 |
| Memantine | 12 | $995 | $83 |
| Ezetimibe | 15 | $867 | $58 |
| Atorvastatin | 23 | $716 | $31 |
| Tamsulosin | 16 | $496 | $31 |
| Metoprolol | 11 | $380 | $35 |
| Benazepril | 31 | $269 | $9 |
| Amlodipine Besylate | 37 | $250 | $7 |
| Trazodone | 15 | $216 | $14 |
| Olanzapine | 12 | $146 | $12 |
| Losartan | 16 | $137 | $9 |
| Hydrochlorothiazide | 36 | $135 | $4 |
| Escitalopram | 17 | $126 | $7 |
| Simvastatin | 15 | $67 | $4 |
2019: 10 drugs
| Synthroid | 22 | $1,429 | $65 |
| Atorvastatin | 28 | $840 | $30 |
| Ezetimibe | 12 | $718 | $60 |
| Metoprolol | 22 | $587 | $27 |
| Amlodipine Besylate | 31 | $345 | $11 |
| Benazepril | 35 | $343 | $10 |
| Zolpidem | 21 | $145 | $7 |
| Hydrochlorothiazide | 23 | $107 | $5 |
| Omeprazole | 12 | $107 | $9 |
| Oxycodone | 13 | $73 | $6 |
2018: 12 drugs
| Ezetimibe | 13 | $1,743 | $134 |
| Metoprolol | 13 | $810 | $62 |
| Atorvastatin | 26 | $776 | $30 |
| Finasteride | 16 | $568 | $35 |
| Amlodipine Besylate | 36 | $490 | $14 |
| Hydrochlorothiazide | 28 | $254 | $9 |
| Oxycodone | 19 | $219 | $12 |
| Benazepril | 25 | $204 | $8 |
| Hydrocodone-Acetaminophen | 17 | $159 | $9 |
| Zolpidem | 19 | $157 | $8 |
| Omeprazole | 18 | $108 | $6 |
| Tramadol | 12 | $33 | $3 |
2017: 15 drugs
| Atorvastatin | 37 | $1,222 | $33 |
| Galantamine Er | 12 | $908 | $76 |
| Metoprolol | 13 | $672 | $52 |
| Oxycodone | 37 | $405 | $11 |
| Amlodipine Besylate | 52 | $322 | $6 |
| Hydrochlorothiazide | 31 | $258 | $8 |
| Hydrocodone-Acetaminophen | 40 | $254 | $6 |
| Benazepril | 30 | $248 | $8 |
| Finasteride | 15 | $248 | $17 |
| Clonazepam | 19 | $155 | $8 |
| Gabapentin | 14 | $132 | $9 |
| Tramadol | 16 | $68 | $4 |
| Lisinopril | 12 | $62 | $5 |
| Zolpidem | 12 | $50 | $4 |
| Simvastatin | 11 | $46 | $4 |
2016: 22 drugs
| Benicar | 12 | $1,631 | $136 |
| Acyclovir | 11 | $1,177 | $107 |
| Premarin | 14 | $1,008 | $72 |
| Desloratadine | 13 | $774 | $60 |
| Atorvastatin | 35 | $730 | $21 |
| Levothyroxine | 14 | $482 | $34 |
| Oxycodone | 23 | $423 | $18 |
| Galantamine Er | 12 | $389 | $32 |
| Amlodipine Besylate | 51 | $380 | $7 |
| Allopurinol | 20 | $354 | $18 |
| Benazepril | 27 | $345 | $13 |
| Metoprolol | 11 | $319 | $29 |
| Hydrochlorothiazide | 34 | $317 | $9 |
| Pravastatin | 12 | $296 | $25 |
| Hydrocodone-Acetaminophen | 22 | $259 | $12 |
| Finasteride | 16 | $247 | $15 |
| Losartan | 20 | $243 | $12 |
| Clonazepam | 18 | $152 | $8 |
| Fluticasone Propionate | 13 | $127 | $10 |
| Medroxyprogesterone Acetate | 14 | $78 | $6 |
| Zolpidem | 12 | $45 | $4 |
| Lovastatin | 11 | $38 | $3 |
2015: 20 drugs
| Lansoprazole | 15 | $1,822 | $121 |
| Desloratadine | 12 | $1,442 | $120 |
| Benicar | 11 | $1,231 | $112 |
| Premarin | 12 | $725 | $60 |
| Oxycodone | 51 | $651 | $13 |
| Tamsulosin | 15 | $643 | $43 |
| Levothyroxine | 23 | $522 | $23 |
| Atorvastatin | 29 | $514 | $18 |
| Hydrocodone-Acetaminophen | 48 | $505 | $11 |
| Amlodipine Besylate | 50 | $494 | $10 |
| Allopurinol | 20 | $403 | $20 |
| Losartan | 31 | $383 | $12 |
| Zolpidem | 22 | $374 | $17 |
| Benazepril | 30 | $331 | $11 |
| Montelukast | 12 | $258 | $21 |
| Hydrochlorothiazide | 24 | $241 | $10 |
| Finasteride | 15 | $146 | $10 |
| Gabapentin | 11 | $93 | $8 |
| Ibuprofen | 11 | $88 | $8 |
| Medroxyprogesterone Acetate | 12 | $64 | $5 |
2014: 21 drugs
| Desloratadine | 11 | $1,322 | $120 |
| Metoprolol | 31 | $1,117 | $36 |
| Oxycodone | 41 | $1,054 | $26 |
| Atorvastatin | 29 | $699 | $24 |
| Amlodipine Besylate | 47 | $634 | $13 |
| Synthroid | 15 | $615 | $41 |
| Premarin | 11 | $555 | $50 |
| Hydrocodone-Acetaminophen | 43 | $416 | $10 |
| Tamsulosin | 11 | $415 | $38 |
| Losartan | 24 | $373 | $16 |
| Benazepril | 25 | $296 | $12 |
| Hydrochlorothiazide | 30 | $291 | $10 |
| Levothyroxine | 18 | $226 | $13 |
| Fluticasone Propionate | 11 | $174 | $16 |
| Zolpidem | 26 | $164 | $6 |
| Finasteride | 14 | $154 | $11 |
| Warfarin | 20 | $142 | $7 |
| Allopurinol | 11 | $134 | $12 |
| Terazosin | 18 | $106 | $6 |
| Ibuprofen | 16 | $76 | $5 |
| Medroxyprogesterone Acetate | 12 | $45 | $4 |
2013: 23 drugs
| Diovan | 17 | $2,665 | $157 |
| Micardis | 11 | $1,525 | $139 |
| Metoprolol | 24 | $1,003 | $42 |
| Atorvastatin | 31 | $898 | $29 |
| Premarin | 14 | $841 | $60 |
| Amlodipine Besylate | 51 | $738 | $14 |
| Omeprazole | 14 | $666 | $48 |
| Oxycodone | 32 | $639 | $20 |
| Hydrocodone-Acetaminophen | 52 | $607 | $12 |
| Montelukast | 12 | $472 | $39 |
| Losartan | 21 | $347 | $17 |
| Potassium Chloride | 11 | $319 | $29 |
| Benazepril | 29 | $312 | $11 |
| Hydrochlorothiazide | 32 | $205 | $6 |
| Terazosin | 16 | $201 | $13 |
| Gabapentin | 14 | $160 | $11 |
| Zolpidem | 15 | $143 | $10 |
| Allopurinol | 13 | $142 | $11 |
| Quetiapine | 11 | $129 | $12 |
| Famotidine | 17 | $119 | $7 |
| Mirtazapine | 12 | $104 | $9 |
| Furosemide | 12 | $65 | $5 |
| Medroxyprogesterone Acetate | 12 | $53 | $4 |
Professional record
- NPI
- 1194781351
- Licence
- CA G73842California G73842: Current · expires 2028-02-29
- Trained
- University of California, San Diego School of Medicine, 1990 · 36 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G738420
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 1635 Divisadero St, Ste. 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-04-25
- NPI last updated
- 2012-08-31
This is when the NPI record was last certified, not a medical board exam.